Literature DB >> 33738047

1-Pyrazolyl-5,6-Disubstituted Indazole Derivatives as LRRK2 Inhibitors for Treating Parkinson's Disease.

Ram W Sabnis1.   

Abstract

Entities:  

Year:  2021        PMID： 33738047      PMCID： PMC7957909          DOI： 10.1021/acsmedchemlett.1c00054

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

Review 1.  Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease.

Authors:  Susanna Cogo; Claudia Manzoni; Patrick A Lewis; Elisa Greggio
Journal:  J Neurochem       Date:  2019-11-24       Impact factor: 5.372

Review 2.  Parkinson disease.

Authors:  R Balestrino; A H V Schapira
Journal:  Eur J Neurol       Date:  2019-11-27       Impact factor: 6.089

Review 3.  New hopes for disease modification in Parkinson's Disease.

Authors:  Werner Poewe; Klaus Seppi; Kathrin Marini; Philipp Mahlknecht
Journal:  Neuropharmacology       Date:  2020-04-13       Impact factor: 5.250

Review 4.  Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease.

Authors:  Matthew Taylor; Dario R Alessi
Journal:  Curr Opin Cell Biol       Date:  2020-02-07       Impact factor: 8.382

Review 5.  Immunotherapy for Parkinson's disease.

Authors:  Aaron D Schwab; Mackenzie J Thurston; Jatin Machhi; Katherine E Olson; Krista L Namminga; Howard E Gendelman; R Lee Mosley
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.